Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Former Sen. Ben Sasse is taking Revolution Medicines’ daraxonrasib, which has shown promise as a treatment for pancreatic cancer.
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Former Sen. Ben Sasse is taking Revolution Medicines’ daraxonrasib, which has shown promise as a treatment for pancreatic cancer.
Crypto treasury firms deserve closer attention and these four are buying opportunities, says TD Cowen
TD Cowen is initiating coverage on four crypto treasury firms – public companies who make it their job to buy and hold crypto to increase shareholder value.
Stocks making the biggest moves midday: Palantir, Marvell, CoreWeave, Zscaler & more
Here are the names making headlines in midday trading.
Michael Burry says he’s still betting against Palantir after Trump post boosts stock
The investor of the “Big Short” fame said he continues to hold long-dated put options on the artificial intelligence software firm.
Trump praises Palantir with stock down 14% this week as Iran conflict drags on
Palantir’s Maven platform have reportedly been used in the U.S. military campaign in Iran.
Buy this Israeli defense stock because of its ‘battlefield tested tech,’ Bank of America says
Elbit Systems has rallied 60% in less than four months. One analyst says it will continue to gain as global demand for defense technology stays high.
White House warned staff against making Iran war bets on prediction markets
The warning came after a flurry of unusual activity on oil and stock futures markets shortly before President Trump said he would pause attacks on Iran.
Airports could face a jet fuel crunch within 3 weeks as airlines weigh flight cancellations
Europe’s Airport Industry said if the Strait of Hormuz doesn’t reopen “systemic jet fuel shortage is set to become a reality for the EU.”
The ‘lines draw themselves’ and all say ‘sell Palantir,’ says Carter Worth
From the point of view of technical analysis based on price charts, all the recent action in Palantir points in one direction.